Novo Nordisk has announced it will lower the price of its weight loss medication Wegovy to $499 per month for certain patients who pay out-of-pocket. This change primarily targets uninsured and commercially insured patients not covered by their plans. While this move may increase patient access, it does not help those on government insurance programs like Medicare and Medicaid, who often face much higher costs. By offering the product through an online pharmacy, Novo Nordisk aims to control distribution better as cheaper alternatives loom on the market.
Novo Nordisk's decision to lower the price of Wegovy to $499 per month for uninsured or commercially insured patients aims to increase accessibility for those paying out-of-pocket.
Despite the pricing change, many patients on government insurance remain unable to access affordable options for Wegovy, paying up to $1,300 monthly out-of-pocket at community pharmacies.
Collection
[
|
...
]